Technologies Driving Precision Medicine

LONDON, Nov. 2, 2017 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/5171220

Targeted and personalized therapeutics are likely to transform the existing precision medicine landscape. With recent landmark regulatory approval, CAR T therapy has the potential to emerge as the industry standard for cancer management in the future and potentially replace existing treatment techniques. Bispecific and multi-specific antibody platforms are likely to emerge as the preferred alternatives for existing monotherapy strategies as they offer increased therapeutic efficacy, while reducing off-target effects.

This global research service provides comprehensive insights across key technologies, research trends, funding IP outlook, clinical trials and industry innovations that are likely to transform the landscape of chimeric antigen receptor (CAR) T cell and bispecific/multi-specific T cell engaging immunotherapies.

Download the full report: https://www.reportbuyer.com/product/5171220

About Reportbuyer

Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

https://www.reportbuyer.com

For more information:

Sarah Smith

Research Advisor at Reportbuyer.com

Email: query@reportbuyer.com

Tel: +44 208 816 85 48

Website: www.reportbuyer.com

View original content:http://www.prnewswire.com/news-releases/technologies-driving-precision-medicine-300548376.html

SOURCE ReportBuyer